Copenhagen, October 8 2024
Synamics Therapeutics, a pioneering startup in AI-driven oncology drug discovery, is excited to announce its participation in the NVIDIA Inception Program. This global initiative supports startups during critical growth phases by providing access to NVIDIA's cutting-edge technology, AI models, and expert resources to accelerate development.
As part of NVIDIA Inception, Synamics will leverage advanced tools like BioNeMo, an AI-powered cloud service for drug discovery. These resources will further enhance Synamics' proprietary platform, Dynaptive, which designs adaptive drugs to effectively combat cancer drug resistance.
“Synamics is committed to revolutionizing cancer treatment by predicting and counteracting drug resistance from the very early phases of drug design. Joining the NVIDIA Inception Program is a significant step forward for us, providing unparalleled access to resources that will advance our platform and accelerate our drug discovery efforts,” said Violet Zahedi, CEO of Synamics Therapeutics.
Synamics is poised to disrupt oncology treatment, and participation in NVIDIA Inception will help the company bring breakthrough treatments to market faster.
For more information contact us at info@synamics.com.
© 2023 NVIDIA, and the NVIDIA logo are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries.
Comments